New milestones ahead in complement-targeted therapy.

Area of Science:

• Immunology
• Pharmacology
• Drug Discovery

Background:

• The complement system, a key part of innate immunity, can paradoxically harm the host, causing or worsening inflammatory and degenerative conditions.
• Therapeutic inhibition of complement has long been recognized as valuable, but clinical translation has been slow despite initial successes.

Purpose of the Study:

• To review recent advancements in complement-targeted drug discovery and development.
• To provide an overview of current and emerging complement inhibitor therapies.
• To discuss future directions for clinically available complement therapeutics.

Main Methods:

• Review of preclinical and clinical data on complement inhibitors.
• Analysis of current trends in complement-targeted drug development, including various molecular modalities.
• Evaluation of clinical trial progress for complement inhibitors in rare and prevalent diseases.

Main Results:

• A growing pipeline of complement inhibitors targeting various points in the complement cascade is in clinical development.
• Antibody-based drugs are prevalent, but novel small molecules, peptides, proteins, and oligonucleotides offer new therapeutic options.
• Complement inhibitors are expanding from rare diseases to more common conditions, with increasing clinical experience informing target selection and safety.

Conclusions:

• Despite challenges, complement inhibitors show proven effectiveness and renewed interest, with numerous candidates in late-stage trials.
• Diverse drug modalities and expanding indications suggest a promising future for complement-targeted therapies.
• Continued research and clinical experience are crucial for optimizing the next generation of complement therapeutics.